Gubra: Wrap up from interview with CEO Henrik Blou and CFO Kristian Borbos
Gubra’s strong CRO-financials and obesity exposure no longer a secret – stock price soaring
Gubra’s share price was up almost 10 percent yesterday as the company released its annual 2023 report showing impressive and slightly better than expected organic growth of 29 percent in the CRO business and an EBIT-margin of 27,4 percent. Following the release, Gubra management CEO Henrik Blou and CFO Kristian Borbos participated in an event with HCA where they presented highlights from the annual report and gave an update on the broad based – but primarily obesity focused - pipeline.
As usual, management was very confident when asked to describe the prospects of Gubra, in particular how Gubra would likely be able to position themselves meaningfully in the gigantic obesity market currently dominated Novo Nordisk and Eli Lilly as Gubra’s pipeline projects includes combination treatments to existing obesity products and addresses different patients types etc.
Up almost 50 percent this year, some Gubra investors probably starts questioning if the Gubra stock is getting ahead of itself, but others suggesting the development merely reflect the typical pattern seen when stocks move from small to mid-cap status; while the strong growth and high margin in the CRO business as well as the potentially highly valuable obesity focused pipeline validated through Big Pharma partnerships are well known characteristics of Gubra to many Danish investors, the strong share price development the last month could reflect that international investors are starting to better understand the Gubra investment case. As these investors have seen other obesity stocks like Novo Nordisk, Zealand Pharma and Eli Lilly appreciate massively the last couple of years, they will likely look for new ways to get obesity exposure – Gubra being one of the possibilities as it is no longer ‘too small’ to invest in.
You can see the event at this link: Gubra interview
Disclaimer: HC Andersen Capital receives payment from Gubra for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 8:35 AM 29-02-2024.
Login required
This content is only available for logged in users
Gubra
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Read more on company page